 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
Adult:
12.5 mg 1-2 times on day 1 followed by 25 mg 1-2 times on day 2, increased gradually in increments of 25-50 mg up to a daily dose of 300 mg within 14-21 days. Subsequent increments of 50-100 mg may be made 1-2 times wkly. Usual dose: 200-450 mg/day. Max: 900 mg/day.
Elderly: Initially, 12.5 mg on day 1 increased subsequently by increments of 25 mg. |
| |
| Oral |
| MANAGEMENT OF PSYCHOSES IN PARKINSONISM |
| Adult:
Initially, 12.5 mg once daily at night, increased in steps of 12.5 mg up to 2 times each wk, not >50 mg/day at the end of the 2nd wk. Usual dose: 25-37.5 mg daily. Max: 100 mg daily. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Leucocyte counts should be monitored regularly and for at least 4 wk after treatment discontinuation. Renal, hepatic or cardiac impairment; prostatic enlargement, narrow-angle glaucoma; elderly; immobilised patients |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Drowsiness, dizziness, headache; nausea, vomiting, constipation; anxiety, confusion, fatigue, transient fever. Rarely, dysphagia, acute pancreatitis, cholestatic jaundice; orthostatic hypotension, tachycardia; seizures; hypersalivation. |
| |
|
| Adverse Drug Reactions |
Rarely, thromboembolism. Reversible neutropenia which may progress to a potentially fatal agranulocytosis. Fatal myocarditis. |
| |
|
| Interactions |
Concurrent use with bone marrow suppressants e.g. carbamazepine, co-trimoxazole, chloramphenicol, penicillamine, sulfonamides, antineoplastics or pyrazolone analgesics; long-acting depot antipsychotics. Reduced plasma concentrations with concomitant use of phenytoin. May enhance the central effects of MAOIs. |
| |
|
|
|
